References
- Cantero M, Millán-Pérez R, Muñez E, et al. SARS-COV-2 seroprevalence among all healthcare workers in a tertiary hospital in Spain. Infect Dis (Lond). 2022;54(1):8–15.
- Gong F, Wei HX, Li Q, et al. Evaluation and comparison of serological methods for COVID-19 diagnosis. Front Mol Biosci. 2021;23:8.
- Hsieh WY, Lin CH, Lin TC, et al. Development and efficacy of lateral flow point-of-Care testing devices for rapid and mass COVID-19 diagnosis by the detections of SARS-CoV-2 antigen and anti-SARS-CoV-2 antibodies. Diagnostics. 2021;11(10):1760.
- Spicuzza L, Montineri A, Manuele R, et al. Reliability and usefulness of a rapid IgM-IgG antibody test for the diagnosis of SARS-CoV-2 infection: a preliminary report. J Infect. 2020;81(2):e53–e54.
- Ghaffari A, Meurant R, Ardakani A. COVID-19 point-of-Care diagnostics that satisfy global target product profiles. Diagnostics. 2021;11(1):115.
- Chansaenroj J, Yorsaeng R, Posuwan N, et al. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients. Virol J. 2021;18(1):52.
- Kallaste A, Kisand K, Aart A, et al. Antibody levels remain high to one-year's follow-up after moderate and severe COVID-19, but not after mild cases. Infect Dis. 2021. DOI:https://doi.org/10.1080/23744235.2021.2018492
- Wang P, Liu L, Nair MS, et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020;9(1):2091–2093.
- World Health Organization. COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.0.1; 2020. Available from: https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1.
- Pecoraro V, Cassetti T, Meacci M, et al. Accuracy of the serological detection of IgG and IgM to SARS-Cov-2: a prospective, cross-sectional study. Eur J Clin Microbiol Infect Dis. 2021;40(9):1891–1898.